Original InvestigationsCardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency☆,☆☆
Section snippets
Patient population
This was a prospective, cross-sectional, multicenter study of consecutive adult patients seen in four nephrology outpatient clinics across Canada (Halifax, London, Saskatoon, and Vancouver). The study was purely descriptive, and no therapeutic interventions were proscribed. All patients seen for routine follow-up of CRI during the 4-week study period in 1999 were eligible for enrollment. Only patients with CRI, defined by abnormal serum creatinine levels documented at least twice (>1 month
Results
Three hundred four consecutive eligible patients were enrolled onto the study. Demographic characteristics of study patients are listed in Table 1.
Age (y) 60.8 ± 15.7 Sex (% men) 61.8 Race (%) White 87.3 Asian 4.3 Black 2.7 Aboriginal 2.3 Kidney disease (%) Glomerulonephritis 28.8 Diabetic nephropathy 27.1 Ischemic renal disease 23.4 Interstitial renal disease 11.2 Polycystic kidney disease 5.3 Proteinuria >1 g/24 h (%) 65.3 Creatinine clearance (mL/min) 30.3 ±
Discussion
CVD was common (38.5%) in this cohort of patients with CRI. This figure is similar to the prevalence of coronary disease in hemodialysis and peritoneal dialysis patients.1 A previous cohort of Canadian patients with CRI and similar levels of residual kidney function, assembled between 1994 and 1997, also found the prevalence of CVD to be approximately 40%.18 Interestingly, the prevalence of CVD in a community-based cohort of patients with milder renal insufficiency (serum creatinine level, 1.5
Acknowledgements
Acknowledgment: The authors thank Anu Jindal for assistance with data entry.
References (30)
- et al.
Clinical epidemiology of cardiovascular disease in chronic renal disease
Am J Kidney Dis
(1998) - et al.
Cardiovascular disease and chronic renal disease: A new paradigm
Am J Kidney Dis
(2000) - et al.
Marked reduction in long-term cardiac deaths with aspirin after a coronary event. Multicenter Myocardial Ischemia Research Group
J Am Coll Cardiol
(1996) - et al.
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
Am J Cardiol
(1996) - et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
Lancet
(1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start?
Am J Kidney Dis
(1998)- et al.
Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
Am J Kidney Dis
(1999) - et al.
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
Kidney Int
(1999) Hyperlipidemia in patients with chronic renal disease
Am J Kidney Dis
(1998)- et al.
Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group
Am J Med
(1998)
Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease
Am J Kidney Dis
Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on Cardiovascular Disease
J Am Soc Nephrol
Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
BMJ
The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction
Circulation
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
Lancet
Cited by (200)
Unstable Carotid Plaque as a Phenotype of Chronic Systemic Inflammation Enhances Renal Insufficiency
2020, Journal of Stroke and Cerebrovascular DiseasesThe Lancet Kidney Campaign: An opportunity for partnerships
2016, The LancetNon-cardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: A systematic review and meta-analysis
2015, International Journal of CardiologyCitation Excerpt :Non-cardiovascular (CVD) comorbidity is common in heart failure (HF) and is well known to influence its prognosis [1,2] which may occur through shared risk factors [3,4] or direct pathophysiological links [5–8].
Consensus statement on management of dyslipidemia in Indian subjects
2014, Indian Heart Journal
- ☆
Supported in part by Biomedical Research Fellowships from the Kidney Foundation of Canada (M.T. and J.G.) and Baxter Corporation (M.T.).
- ☆☆
Address reprint requests to Bryce A. Kiberd, MD, Rm 5077, AAC Dickson Bldg, 5820 University Ave, Halifax, Nova Scotia, B3H 1V8, Canada. E-mail: [email protected]